“I am looking forward to chairing this panel of cardiovascular leaders,” said Walpole.
Freeport, The Bahamas (PRWEB) February 14, 2013
Okyanos Heart Institute, which brings a new standard of care and better quality of life to patients with chronic coronary artery disease using cardiac stem cell therapy, announces that chief medical officer and interventional cardiologist Howard T. Walpole Jr., M.D., MBA, FACC, FACAI will speak at The American College of Cardiology’s (ACC’s) 13th Annual Scientific Session. Dr. Walpole will chair a panel of experts on the topic of “Down and Dirty Problems for Cardiovascular Leaders”. The panel will teach cardiologists in leadership roles in their practice, hospital, or academic group how to have difficult conversation with their faculty and staff on issues such as improving poor outcomes, increasing productivity, and making efficient decisions without compromising quality. The session will be held from 12:15 p.m. to 1:45 p.m. on Saturday, March 9 at the Moscone Center in San Francisco.
“I am looking forward to chairing this panel of cardiovascular leaders,” said Walpole. “The ACC provides a comprehensive forum not only for medical and scientific advances, but also the day-to-day challenges we encounter in running our practices and managing staff. The applied skills and training are often as valuable as the knowledge gained in advances in medicine.”
Matt Feshbach, ceo of Okyanos Heart Institute, said, “We are proud of Dr. Walpole’s commitment to and leadership in the field of cardiovascular training and education. He is a stellar example of how to run a world-class medical facility with uncompromising quality standards.”
More information about the event can be found at http://www.cardiosource.org/acc.
ABOUT OKYANOS HEART INSTITUTE:
Based in Freeport, The Bahamas, Okyanos Heart Institute adheres to U.S. surgical center standards and is led by Chief Medical Officer Howard T. Walpole Jr., M.D., MBA, FACC, FACAI, and a leader of the American College of Cardiology for many years. The mission of Okyanos Heart Institute is to bring a new standard of care and a better quality of life to patients with chronic coronary artery disease using cardiac stem cell therapy. Okyanos Treatment utilizes cardiac stem cell therapy, a unique blend of stem and regenerative cells to support the growth of new blood vessels and to assist the heart in repairing tissue damaged by heart attack and disease. The Greek god of rivers, “Okyanos” symbolizes the primary mechanism of action that these adult stem cells have on ischemic (lack of blood flow) heart tissue, the result of the plaque deposits in the coronary arteries. The stem cells, derived from a person’s adipose (fat) tissue, create new blood vessels, a process known as angiogenesis. The treatment helps to facilitate blood flow in the heart and intake and use of oxygen, as measured by a rigorous clinical trial known as the PRECISE trial, as well as cardiac cell therapy trials at leading research institutions. For more information, log on to http://www.okyanos.com/.